Orencia intravenous is considered medically necessary when the following non-preferred product exception criteria are met.
General approval for Non-Preferred Orencia IV: A) Approve for 6 months if patient meets BOTH of the following (i and ii)
Applies to initial non-preferred exception approvals per section 1
Criterion i: Standard PA policy: Patient meets the standard Inflammatory Conditions - Orencia Intravenous Prior Authorization Policy criteria
Referenced standard PA criteria required for all approvals
Criterion ii: Trial or clinical rationale: Patient meets ONE of the following: a) Patient has tried two of the specified agents (examples include tocilizumab subcutaneous products such as Actemra, Avtozma, Tyenne; Enbrel; an adalimumab product; Rinvoq/Rinvoq LQ; or tofacitinib formulations) — documentation required; OR b) According to the prescriber, the patient has heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, OR a demyelinating disorder.
Trials of multiple products within the same drug class (e.g., multiple adalimumab products or multiple tocilizumab products) count as one product; trials of both formulations of the same agent (e.g., tofacitinib and tofacitinib XR or Rinvoq and Rinvoq LQ) count collectively as one product. Documentation required as noted in policy.
When Step 1/2a review is permitted: B) If the patient meets the standard PA criteria but does not meet the trial/clinical rationale requirement, a request for a Step 1 or Step 2a preferred product may be reviewed using the respective standard Inflammatory Conditions - Prior Authorization Policy criteria.
Step 1/2a examples include Actemra subcutaneous, Avtozma subcutaneous, Tyenne subcutaneous, Enbrel, select adalimumab NDCs and biosimilars, Rinvoq, and generic tofacitinib formulations (lists vary by indication).
Indication-specific initial therapy rules: For Psoriatic Arthritis initial therapy: Approve for 6 months if patient meets BOTH criteria (standard PA criteria AND has tried TWO of Enbrel, an adalimumab product, Otezla/Otezla XR, Rinvoq/Rinvoq LQ, Skyrizi subcutaneous, Sotyktu, an ustekinumab subcutaneous product, Taltz, Tremfya, or tofacitinib/XR) OR meets prescriber-cited contraindication reasons.
See policy for full lists and counting rules for trials.
Patients currently receiving Orencia: Approve for 1 year if patient meets the standard PA criteria AND meets ONE of the following (a–f): a) Rheumatoid arthritis: has tried TWO of a tocilizumab subcutaneous product, Enbrel, an adalimumab product, Rinvoq, or tofacitinib/XR; OR b) Juvenile idiopathic arthritis: has tried TWO of a tocilizumab subcutaneous product, Enbrel, an adalimumab product, Rinvoq/Rinvoq LQ, or tofacitinib formulations; OR c) Psoriatic arthritis: has tried TWO of Enbrel, an adalimumab product, Otezla/Otezla XR, Rinvoq/Rinvoq LQ, Skyrizi subcutaneous, Sotyktu, an ustekinumab subcutaneous product, Taltz, Tremfya, or tofacitinib/XR; OR d) Established on Orencia intravenous for at least 90 days; OR e) Prescriber documents heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, OR a demyelinating disorder; OR f) Established on Orencia subcutaneous for at least 90 days with prescription claims indicating at least a 90-day supply dispensed within the past 130 days (verification required) — if claims history unavailable, prescriber verification allowed.
Multiple pathway options (a–f) allow continuation coverage; documentation or claims verification required where specified.